SavedAdd your journal

Journals / Genel Tıp Dergisi / 2004 / Cilt: 14 - Sayı: 2

Are fixed oils of Sesamum indicum L. and Apium graveolens L. protective against hepatotoxicity?

Sesamum indicum L. ve Apium graveolens L. ekstreleri karboplatin hepatotoksisitesine karşı koruyucu mu?

HANEFİ ÖZBEK
Mustafa KÖSEM
ENDER ERDOĞAN
FEVZİ ÖZGÖKÇE
Pages
49–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: FOS and FOA appears to be partially effective in alleviating carboplatin-induced hepatotoxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Effects of Sesamum indicum L. and Apium graveolens L. extracts against carboplatin-induced hepatotoxicity were aimed to investigate in rats in this study.
📊
Key Findings & Data:The FOS and the FOA groups displayed significantly lower ALT, ALP and indirect bilirubin levels compared to the carboplatin group.
💡
Conclusion & Impact:Conclusion: FOS and FOA appears to be partially effective in alleviating carboplatin-induced hepatotoxicity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Apium graveolens · Sesamum · Sıçan

Abstract

Objective: Effects of Sesamum indicum L. and Apium graveolens L. extracts against carboplatin-induced hepatotoxicity were aimed to investigate in rats in this study. Method: Sprague-Dawley rats were divided into six groups and given isotonic saline solution (ISS), carboplatin, carboplatin+fixed oil of Sesamum indicum L. (FOS), carboplatin+fixed oil of Apium graveolens L. (FOA), carboplatin+vitamin C and carboplatin+vitamin E, respectively. Results: In histological examination of liver sections none of the groups exhibited pathological changes. The liver injury was evidenced by rise of serum ALT, ALP and indirect bilirubin levels in carboplatin group compared to the controls. The FOS and the FOA groups displayed significantly lower ALT, ALP and indirect bilirubin levels compared to the carboplatin group. The only difference from the ISS group was elevation of ALP level in FOS. Vitamin C and E displayed similar biochemical changes as FOS and FOA. Body weights were similar in ISS, carboplatin and FOS groups throughout the study but progressively decreased in FOA, vitamin C and vitamin E groups. Conclusion: FOS and FOA appears to be partially effective in alleviating carboplatin-induced hepatotoxicity.

Özet

Amaç: Bu çalışmada karboplatinin sıçan karaciğerinde yaptığı toksisite üzerine Sesamum indicum L. ve Apium graveolens L. ekstrelerinin koruyucu etkileri araştırıldı. Yöntem: Sprague-Dawley ırkı sıçanlardan oluşturulan gruplara serum fizyolojik (SF), karboplatin, karboplatin+Sesamum indicum L. (susam) sabit yağı (SSY), karboplatin+Apium graveolens L. (kereviz) sabit yağı (KSY), karboplatin+C vitamini ve karboplatin+E vitamini uygulandı. Bulgular: Çalışma gruplarına ait karaciğerlerde histopatolojik bulguya rastlanmadı. Serum ALT, ALP ve indirekt bilirubin seviyeleri karboplatin grubunda SF kontrol grubuna göre anlamlı derecede yüksekti ve karboplatinin biyokimyasal enzimler düzeyinde karaciğer hasarı yaptığı şeklinde yorumlandı. SSY ve KSY’nin ALT, ALP, AST ve indirekt bilirubin düzeyleri karboplatin grubundan anlamlı derecede düşüktü. Yalnızca SSY grubunun ALP değeri SF kontrol grubundan yüksek olarak tespit edildi, bunun dışında SSY ve KSY ile SF kontrol grubu arasında anlamlı bir farklılık saptanmadı. C vitamini ve E vitamini gruplarına ait biyokimyasal değerler de SSY ve KSY’na benzer şekilde bulundu. SF, karboplatin ve SSY gruplarının günlük vücut ağırlığı değişimi birbirine benzer seyretti. KSY, C vitamini ve E vitamini gruplarının günlük vücut ağırlığı değişimi ise gittikçe azalan bir seyir gösterdi. Sonuç: SSY ve KSY’nin karboplatine bağlı karaciğer toksisitesini kısmen önleyebileceği sonucuna varıldı.

🔖

Cite This Article

ÖZBEK, H., KÖSEM, M., ERDOĞAN, E., ÖZGÖKÇE, F. (2004). Are fixed oils of Sesamum indicum L. and Apium graveolens L. protective against hepatotoxicity?. Genel Tıp Dergisi, Cilt: 14 - Sayı: 2, 49–55. https://ajindex.com/articles/224993

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Katzung BG. Basic&Clinical Pharmacology, In: Cancer Chemotherapy. 6th edition, Ed. Salmon SE, Sartorelli AC. Lebanon; 1995, p. 831
  2. Kayaalp SO. Rasyonel tedavi yönünden Tıbbi Farmakoloji, Cilt I, dokuzuncu baskı, Ankara: Hacettepe Taş; 2000
  3. Carles J, Nogue M, Domenech M, Perez C, Saigi E, Villadiego K, et al. Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function. Oncology 2000;59:24-7
  4. Chang AY, Hui L, Asbury R, Boros L, Garrow G, Rubins J. Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. Cancer Chemother Pharmacol 1999;44 Suppl:S26-8
  5. Shi TZ, Yan JL. Therapeutic effect of carboplatin and etoposide combinative therapy on 123 lung cancer cases. Zhonghua Zhong Liu Za Zhi 1994;16:384-6
  6. Hardman GJ, Limbird Lee E, Molinoff PB, Ruddon RW, Gilman AG. Goodman Gilman’s the pharmacological basis of therapeutics. In: Antineoplastic agents. 9th ed. Ed. Chabner BA, Allegra CJ, Curt GA et al. International edition: The McGraw-Hill Companies; 1996, p.1237
  7. Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connaghan DG, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996;14:1156-64
  8. Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995;1:40-6
  9. Jones RB, Shpall EJ, Ross M, Coniglio D, Affronti ÖML, Peters WP. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: Excessive hepatic toxicity. Cancer Chemother Pharmacol 1990;26:155-6
  10. Demirer T, Ilhan O, Mandel NM, Arat M, Gunel N, Celebi H, et al. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies. Bone Marrow Transplant 2000;25:697-703
  11. Welborn JL, Kopecky KJ, Meyers FJ, Veith R, Shurafa M, Doroshow JH, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia: A Southwest Oncology Group trial. Leukemia 1995;9:1126-9
  12. Chu G, Mantin R, Shen YM, Baskett G, Sussman H. Massive cisplatin overdose by accidental substitut